Six Abstracts of Kelun-Biotech's Clinical Studies Published at the 2025 ASCO Annual Meeting

Six Abstracts of Kelun-Biotech's Clinical Studies Published at the 2025 ASCO Annual Meeting

CHENGDU, China, May 23, 2025 /PRNewswire/ -- The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting is scheduled to take place in Chicago, Illinois, USA from May 30 to June 3. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK,...

Lethal mutations in pregnancy loss

Lethal mutations in pregnancy loss

REYKJAVIK, Iceland, May 21, 2025 /PRNewswire/ -- In a study published in Nature today "Sequence diversity lost in early pregnancy," scientists from deCODE genetics, a subsidiary of Amgen, estimate that around one in 136 pregnancies are lost due to...

Progress closing the mobile internet gender gap stalls in LMICs: GSMA Mobile Gender Gap Report 2025

Progress closing the mobile internet gender gap stalls in LMICs: GSMA Mobile Gender Gap Report 2025

Women are 14% less likely than men to use mobile internet in LMICs, with 885 million remaining unconnected LONDON, May 14, 2025 /PRNewswire/ -- Progress in closing the gender gap in mobile internet use across LMICs stalled in 2024, according to the...

Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy

Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy

MELBOURNE, Australia and INDIANAPOLIS, May 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been...

CGTN: How China speeds up AI development, advances high-quality Global South cooperation

CGTN: How China speeds up AI development, advances high-quality Global South cooperation

BEIJING, April 30, 2025 /PRNewswire/ -- CGTN published an article on Chinese President Xi Jinping's inspection tour in east China's Shanghai. Focusing on his visits to an AI incubator and the New Development Bank, the article stresses China's...

Yalla Group Releases 2024 ESG Report

Yalla Group Releases 2024 ESG Report

DUBAI, UAE, April 24, 2025 /PRNewswire/ -- Yalla Group Limited ("Yalla" or the "Company") (NYSE: YALA), the largest Middle East and North Africa (MENA)-based online social networking and gaming company, today published its 2024 Environmental, Social...

Eyebright Medical Published its 2024 Environmental, Social and Governance Report

Eyebright Medical Published its 2024 Environmental, Social and Governance Report

Commitment to Sustainable Development, Social Responsibility, and Corporate Governance HONG KONG, April 23, 2025 /PRNewswire/ -- Eyebright Medical Technology (Beijing) Co., Ltd. ("Eyebright Medical", the "Company", Stock Code: 688050.SH, together...

Blueprint for trade stability

Blueprint for trade stability

BEIJING, April 17, 2025 /PRNewswire/ -- Beijing Review has recently published a government white paper titled China's Position on Some Issues Concerning China-US Economic and Trade Relations. While outlining China's vision for resolving tariff...

Clinical research results for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) published in Nature Medicine, a top international medical journal

Clinical research results for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) published in Nature Medicine, a top international medical journal

CHENGDU, China, April 12, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that results from a Phase 3 registrational clinical study evaluating the novel TROP2 antibody drug conjugate (ADC)...

The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine

The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine

CHENGDU, China, April 6, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced that the prestigious medical journal Nature Medicine has published the results from the Phase III trial of its...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • menu
    menu